FDA proposes new classification that formally recognizes NAC as a dietary ingredient, ending its legal gray area
The FDA announced a proposed rule that would create a new regulatory category for N-acetyl-L-cysteine (NAC), a product long sold as a dietary supplement.
Under the proposal, NAC would be classified as a "Dietary Ingredient Not Excluded from the Dietary Supplement Definition," effectively confirming its status as a supplement despite its prior drug approvals.
The change addresses a regulatory gap that arose because the agency had approved NAC as a drug in 1963 for mucus-breaking in lung conditions and in 1974 for treating acetaminophen overdose, and current rules bar approved drugs from being labeled as supplements.
Proponents, including members of the MAHA movement, view the rule as a victory that clarifies the market and removes uncertainty for manufacturers and consumers.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: In a win for MAHA, FDA creates new regulatory category for the supplement NAC”
read at STAT ↗
comments(0)
5-min edit window · permanent after that